MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-17-0957

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2017

Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.

Kwak Jae-Yong, Kim Sung-Hyun, Oh Suk Joong, Zang Dae Young, Kim Hawk, Kim Jeong-A, Do Young Rok, Kim Hyeoung Joon, Park Joon Seong, Choi Chul Won, Lee Won Sik, Mun Yeung-Chul, Kong Jee Hyun, Chung Joo Seop, Shin Ho-Jin, Kim Dae-Young, Park Jinny, Jung Chul Won, Bunworasate Udomsak, Comia Narcisa Sonia, Jootar Saengsuree, Reksodiputro Arry Harryanto, Caguioa Priscilla B, Lee Sung-Eun, Kim Dong-Wook

Клиническое исследование III фазыСравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients newly diagnosed or with insufficient response to other TKIs. This study was conducted to evaluate the efficacy and safety of radotinib as first-line therapy for CML-CP.Experimental

Design

This multinational, open-label study assigned patients (1:1:1) to one of two twice-daily radotinib doses, or imatinib daily. The primary endpoint was major molecular response (MMR) by 12 months.

Results

Two hundred forty-one patients were randomized to receive radotinib 300 mg (n = 79) or 400 mg twice-daily (n = 81), or imatinib 400 mg daily (n = 81). MMR rates by 12 months were higher in patients receiving radotinib 300 mg (52%) or radotinib 400 mg twice-daily (46%) versus imatinib (30%; P = 0.0044 and P = 0.0342, respectively). Complete cytogenetic response (CCyR) rates by 12 months were higher for radotinib 300 mg (91%) versus imatinib (77%; P = 0.0120). Early molecular response at 3 months occurred in 86% and 87% of patients receiving radotinib 300 mg and radotinib 400 mg, respectively, and 71% of those receiving imatinib. By 12 months, no patients had progression to accelerated phase or blast crisis. Most adverse events were manageable with dose reduction.

Conclusions

Radotinib demonstrated superiority over imatinib in CCyR and MMR in patients newly diagnosed with Philadelphia chromosome-positive CML-CP. This trial was registered at www.clinicaltrials.gov as NCT01511289 Clin Cancer Res; 23(23); 7180-8. ©2017 AACR.

Для цитирования: Kwak Jae-Yong, Kim Sung-Hyun, Oh Suk Joong, Zang Dae Young, Kim Hawk, Kim Jeong-A, Do Young Rok, Kim Hyeoung Joon, Park Joon Seong, Choi Chul Won, Lee Won Sik, Mun Yeung-Chul, Kong Jee Hyun, Chung Joo Seop, Shin Ho-Jin, Kim Dae-Young, Park Jinny, Jung Chul Won, Bunworasate Udomsak, Comia Narcisa Sonia, Jootar Saengsuree, Reksodiputro Arry Harryanto, Caguioa Priscilla B, Lee Sung-Eun, Kim Dong-Wook. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017. DOI: 10.1158/1078-0432.ccr-17-0957.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.